Insmed Incorporated (INSM) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Bridgewater, NJ, United States. Der aktuelle CEO ist William H. Lewis.
INSM hat IPO-Datum 2000-06-01, 1,271 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $33.07B.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's commercial product, ARIKAYCE, is an inhaled antibiotic combination therapy approved for treating Mycobacterium avium complex lung disease in adults. Insmed's pipeline includes Brensocatib, an oral inhibitor of dipeptidyl peptidase 1 being developed for bronchiectasis and neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treatment candidate for pulmonary arterial hypertension and other rare pulmonary disorders. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company specializes in addressing unmet medical needs in rare respiratory and systemic diseases.
